Table 2.
Overview of studies including patients with inoperable locally advanced cutaneous squamous cell carcinomas.
| Authors Year |
Study Size | Radiation Protocol No. Patients (Percentage) |
Systemic Therapy No. Patients (Percentage) |
Outcomes | Adverse Events (Grade ≥ 3) No. Patients (Percentage) |
|
|---|---|---|---|---|---|---|
| 1 | Samstein et al.—2014 [59] | 12 | EBRT 12 (100%) 60 Gy (12–80) in 30 fr |
Cetuximab 12 (100%) | RR 64%; DC 91% DSS 2-year 51% OS 2-year 40% |
Dermatitis 2 (16.7%) Thrombocytopenia 2 (16.7%) Mucositis 1 (8.3%) |
| 2 | Lu et al.—2015 [58] | 23 | EBRT 23 (100%) 60 Gy in 30 fr |
N/A | Recurrence 12 (52%) PFS 8 months (1-31) |
N/A |
| 3 | Tanvetyanon et al.—2015 [57] | 61 | EBRT 61 (100%) 60–66 Gy in 30 fr |
Carboplatin or Cisplatin 61 (100%) | Recurrence 50% PS 23.5 months (7.4–39.5) |
Leukopenia 3 (4.9%) Mucositis 3 (4.9%) Neurological 3 (4.9%) |
| 4 | Nottage et al.—2017 [61] | 21 | EBRT 21 (100%) 70 Gy in 35 fr |
Cisplatin 21 (100%) | LC 1-year 61.9% OS 1-year 80.2% DFS 1-year 100% |
Thrombocytopenia 6 (28.6%) Anemia/Fibrosis 5 (23.8%) Hearing loss 4 (19%) Leukopenia/ORN 2 (9.5%) |
| 5 | Joseph et al.—2018 [60] | 8 | EBRT 8 (100%) 55–66 Gy in 22–30 fr |
Cetuximab 8 (100%) | DFS 2-year 87.5% PFS 2-year 83.3% OS 2-year 87.5% |
Dermatitis 4 (50%) ACS/fatigue/mucositis 1 (12.5%) |
| 6 | Cowey et al.—2019 [63] | 82 | EBRT 82 (100%) | Carboplatin and Paclitaxel 22 (26.8%) Cetuximab 20 (24.4%) Cisplatin and 5-FU 6 (7.3%) Cisplatin 5 (6.1%) CarboP, PacliT and Cetux 5 (6.1%) CisP, Cetux and 5-FU 3 (2.7%) Other 21 (25.6%) |
OS 1-year 56.1%; 2-year 30.2%; 3-year 15.6% | N/A |
| 7 | Lavaud et al.—2019 [67] | 4 | Hypofractionated EBRT 4 (100%) 26 Gy in 4 fr |
Pembrolizumab 4 (100%) | PFS 14.4 months OS 15.6 months |
0 (0%) |
| 8 | Fan et al.—2020 [70] | 166 | Hypofractionated EBRT 166 (100%) Photon 92 (55%) Proton 74 (45%) 45 Gy in 12 fr |
Cetuximab 32 (39%) Chemotherapy 30 (36%) Immunotherapy 11 (13%) Combination 10 (12%) |
RR 66% OS 1-year 25.3% PFS 1-year 17.7% |
Dysphagia 11 (6.6%) Trismus 5 (3%) Dermatitis 3 (1.8%) Mucositis/ORN/OSM 1 (0.9%) |
| 9 | Ogata et al.—2020 [64] | 130 | EBRT 62 (48%) | Carbo/Cisplatin 74 (57%) Cetuximab 5 (3.8%) Other 51 (39.2%) |
PFS 5-year platinum 14%, no 22% OS 5-year platinum 29%, no 26% PFS 5-year non-RT 8%, RT 29% OS 5-year non-RT 15%, RT 42% PFS 5-year RT-plat 20%, RT-no 41% OS 5-year RT-plat 25%, RT-no 48% |
Skin ulcer 3 (2.3%) Anemia/Hyponatriemia 2 (1.5%) Duodenal ulcer/Heart failure/Febrile neutropenia/Erythema multiforme 1 (0.8%) |
| 10 | De Felice et al.—2021 [68] | 18 | Ultra-hypofractionated EBRT 18 (100%) 56-64 Gy in 7–8 fr |
N/A | OS 1-year 66%; 2-year 26.4% PFS 1-year 58.7%; 2-year 23.5% |
0 (0%) |
| 11 | Voruganti et al.—2021 [71] | 77 (out of 106 various skin cancers) | SBRT 106 (100%) | N/A | OS 1-year 44%; 2-year 26% PFS 1-year 60%; 2-year 44% |
Dermatitis 31 (29.2%) Mucositis 1 (1%) Skin ulceration 1 (1%) Fibrosis 7 (6.6%) ORN 1 (1%) |
Abbreviations: ACS, Acute coronary syndrome; DC, Disease control; DFS, Disease-free survival; DSS, Disease-specific survival; EBRT, External beam radiation therapy; N/A, Not available; ORN, Osteoradionecrosis; OS, Overall survival; OSM, Osteomyelitis; PFS, Progression-free survival; RR, Response rate.